BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

@article{Tang2021BNT162b2AM,
  title={BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.},
  author={Patrick Tang and Mohammad Rubayet Hasan and Hiam Chemaitelly and Hadi Mohamad Yassine and Fatiha M. Benslimane and Hebah A. Al Khatib and Sawsan AlMukdad and Peter Coyle and Houssein H. Ayoub and Zaina Al Kanaani and Einas Al Kuwari and Andrew Jeremijenko and Anvar Hassan Kaleeckal and Ali Nizar Latif and Riyazuddin Mohammad Shaik and Hanan F. Abdul Rahim and Gheyath K. Nasrallah and Mohamed Ghaith Al Kuwari and Hamad Eid Al Romaihi and Adeel Ajwad Butt and Mohamed H. Al-Thani and Abdullatif Al Khal and Roberto Bertollini and Laith Jamal Abu-Raddad},
  journal={Nature medicine},
  year={2021}
}
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of… 

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

BACKGROUND: Qatar has been experiencing a large SARS-CoV-2 Omicron (B.1.1.529) wave that started on December 19, 2021. We assessed duration of protection of BNT162b2 (Pfizer-BioNTech) and mRNA-1273

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

TLDR
Protection against hospitalization and death appears robust with no evidence for waning for several months after the second dose of Moderna mRNA-1273, but protection against symptomatic infection was consistently higher than that against asymptomatic infection and waned more slowly.

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar

TLDR
Protection afforded by booster doses of the BNT162b2 and mRNA-1273 vaccines is associated with modest effectiveness against symptomatic infection with Omicron, and the development of a new generation of vaccines targeting a broad range of variants may be warranted.

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

TLDR
The BNT162b2 mRNA vaccine offers a substantial protection rate against RT-PCR confirmed COVID-19 caused by the Delta variant upon full vaccination, albeit with slightly reduced effectiveness relative to other strains of SARS-CoV-2.

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

TLDR
The results show that a booster injection of mRNA-1273 more than 6 months after completing the primary two-dose series is safe and elicited nAb titers that were statistically significantly higher than the peak titers detected after the primary vaccination series, suggesting that a boost in vaccine effectiveness might result in increased vaccine effectiveness against infection and disease caused by SARS-CoV-2.

Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection

TLDR
A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed neutralizing antibodies (nAb) response, and this response differed by mRNA vaccine product.

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

TLDR
Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19, however, vaccine effectiveness against infection with the delta variant moderately declined with increasing time since vaccination.

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting

TLDR
VE against infection after two doses of the mRNA vaccine was high initially, but significantly reduced against the delta variant for all three FDA approved vaccines.

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.

TLDR
The findings suggest that jurisdictions facing vaccine supply constraints may benefit from delaying the second dose in younger individuals to more rapidly achieve greater overall population protection against SARS-CoV-2; however, older adults would likely benefit most from minimizing the delay in receiving the second doses to achieve adequate protection against VOC.

Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance

TLDR
The VE-GD framework enables predictions of vaccine protection in real time and offers a rapid evaluation method against novel variants that may inform vaccine deployment and public health responses.
...

References

SHOWING 1-10 OF 49 REFERENCES

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

TLDR
BNT162b2-induced protection against infection appears to wane rapidly after its peak right after the second dose, but it persists at a robust level against hospitalization and death for at least six months following the seconddose.

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.

TLDR
It is shown that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose, and against any COVID-19 hospitalization and death, even after a single dose.

Effectiveness of COVID-19 vaccines against variants of concern, Canada

TLDR
The findings suggest that even a single dose of these 3 vaccine products provide good to excellent protection against symptomatic infection and severe outcomes caused by the 4 currently circulating variants of concern, and that 2 doses are likely to provide even higher protection.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

TLDR
This observational study highlights that while both mRNA COVID-19 vaccines strongly protect against infection and severe disease, further evaluation of mechanisms underlying differences in their effectiveness such as dosing regimens and vaccine composition are warranted.

Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK

TLDR
Limited waning in vaccine effectiveness against hospitalisation and death more than 20 weeks post-vaccination with Vaxzevria or Comirnaty was observed, suggesting that these individuals should be prioritised for booster doses.

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort

TLDR
A large population study of patients tested for SARS-CoV-2 by RT-PCR following two doses of mRNA BNT162b2 vaccine observes a significant increase of the risk of infection in individuals who received their last vaccine dose since at least 146 days ago, particularly among patients older than 60.

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021

TLDR
This report updates vaccine effectiveness (VE) estimates including all COVID-19 vaccines available through August 14, 2021, and examines whether VE differs for adults with increasing time since completion of all recommended vaccine doses.

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.